CMS offers Medicare pricing program exemptions to drugmakers who add Medicaid rebates

The Centers for Medicare & Medicaid Services (CMS) has announced that drug manufacturers can be exempted from two Medicare pricing demonstration programs. The exemption is conditional on the companies agreeing to provide additional rebates for their products in Medicaid.

This policy shift is detailed in internal CMS correspondence obtained by a news outlet. The agency’s approach ties Medicare pricing flexibility to increased rebate activity in the Medicaid market.

The move aims to balance cost controls across the two federal health programs while giving drugmakers a pathway to avoid certain Medicare pricing constraints.

Stakeholders will need to assess how the additional Medicaid rebate requirements affect their pricing strategies and overall profitability.